W. L. Gore & Associates, Inc.
Newark
Delaware
United States
223 articles about W. L. Gore & Associates, Inc.
-
W. L. Gore & Associates, Inc. Receives U.S. Food & Drug Administration (FDA) Approval for Lower Profile Gore® Viabahn® VBX Balloon Expandable Endoprosthesis, Now 6 FR Sheath Compatible
1/31/2024
As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. announced recent FDA approval of a lower profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
-
Gore Initiates Study to Compare the Gore® Viabahn® VBX Balloon Expandable Endoprosthesis to Bare Metal Stents
6/13/2023
W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.
-
Gore PharmBio Introduces 116mL and 232mL Protein Capture Devices With Protein A to Increase Productivity and Throughput for Antibody Purification
4/5/2022
W. L. Gore &Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE ® Protein Capture Devices with Protein A.
-
Gore REDUCE Clinical Study Five-Year Results Demonstrate That PFO Closure With The GORE® CARDIOFORM Septal Occluder Provides Safe Long-Term Reduction Of Recurrent Stroke
3/11/2021
- Published in the New England Journal of Medicine (NEJM), the REDUCE Study continues to show the largest reduction in recurrent ischemic stroke in all PFO shunt sizes over medical therapy alone.*,¹
-
ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes
3/2/2021
Agreement extends research and clinical development across ViaCyte's full product portfolio and Gore's full materials and device proprietary technologies
-
W. L. Gore & Associates Enhances GORE® VIABAHN® Endoprosthesis Portfolio With Lower Profile Delivery
9/22/2020
Improvements to large diameter devices include accessiblity through smaller sheaths while providing enhanced visualization under fluoroscopy
-
Gore PharmBIO Introduces 9.0 mL Protein Capture Device To Improve Throughput And Productivity In Bioprocessing Process Development
5/13/2020
W. L. Gore & Associates, Inc. ("Gore"), a global materials science company, today announced the commercial availability of its new 9.0 mL GORE® Protein Capture Device with Protein A. This new 9.0 mL
-
W. L. Gore & Associates To Reveal New Gender Insights From Real-world Aortic Data At 2019 VEITHsymposium
11/12/2019
Four presentations will highlight data from one of the largest industry-sponsored registries of aortic stent grafts
-
Gore and SCHOTT to Showcase Commercial Option for Packaging and Delivery of Silicone-Sensitive Biologics
10/23/2019
W. L. Gore & Associates, Inc., a global materials science company has collaborated with SCHOTT, a pharma packaging specialist to develop a tested and validated option for packaging and delivery of silicone-sensitive biologics.
-
GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects
6/4/2019
Data from the Gore ASSURED Clinical Study demonstrated 100 percent closure success at six months
-
Gore Receives FDA Approval for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL
5/15/2019
The device and new delivery system combine proven conformability with enhanced placement control to optimize TEVAR outcomes in even complex aortic anatomy
-
Gore to showcase GORE® ENFORM Biomaterial - A New Synthetic and Absorbable Biomaterial for Abdominal Wall Reconstruction - at the American Hernia Society (AHS) Annual Meeting
3/5/2019
GORE ENFORM Biomaterial offers unprecedented conformability and facilitates highly-vascularized, uniform tissue ingrowth
-
GORE® TIGRIS® Vascular Stent Demonstrates High Patency Rates at 12 Months in Treating SFA and PPA Occlusive Lesions in Challenging Patients
1/24/2019
Gore Launches Fracture-Free Assurance Program to reinforce complete confidence in the long-term efficacy and safety of the GORE® TIGRIS® Vascular Stent
-
First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System and Enrolls in Post-Market Registry
9/17/2018
Investigator initiated EXCeL Registry will assess safety and abdominal aortic aneurysm treatment success in patients with challenging anatomies
-
Gore Announces Successful Patient Implant of Endovascular Stent Graft for the Ascending Aorta
8/27/2018
GORE® Ascending Stent Graft, an investigational device, is an off-the-shelf endovascular solution designed to treat life-threatening Type A dissections of the ascending aorta
-
GORE® Molding & Occlusion Balloon for Endovascular Aortic Repair Receives Approval in the United States, Japan, and Europe
8/23/2018
New balloon addresses EVAR stent graft seal and temporary vessel occlusion challenges
-
Gore and Bonbouton Revolutionize Smart Fabric Technology for Practical Digital Health Applications
3/21/2018
Silicon Valley-based Gore Innovation Center enters joint development agreement with graphene sensor startup Bonbouton
-
Jason Field to Succeed Terri Kelly as President and CEO of W. L. Gore & Associates
3/1/2018
Jason Field, global sales and marketing leader for Gore Medical Products Division, will succeed Terri Kelly in the role of President and CEO effective April 1, 2018.
-
First Patient Enrolled in Investigational Study of the GORE EXCLUDER Conformable AAA Endoprosthesis with ACTIVE CONTROL System
1/3/2018
W. L. Gore & Associates announced the first implant of the GORE EXCLUDER Conformable AAA Endoprosthesis in the United States.
-
Gore to Present High-Binding Capacity at Short Residence Time Protein A Chromatography Device at PEGS Europe
11/8/2017
The GORE Protein Capture Device for Rapid mAb Purification enables faster processing times, and the potential to produce a highly concentrated elution pool which may eliminate a process step.